Clinical investigationSotalol for refractory arrhythmias in pediatric and young adult patients: Initial efficacy and long-term outcome☆
References (14)
- et al.
Sotalol: a beta blocker with unique antiarrhythmic properties
Am Heart J
(1987) - et al.
Effectiveness of oral sotalol for treatment of pediatric arrhythmias
Am J Cardiol
(1992) - et al.
Programmed atrial stimulation via the esophagus for management of supraventricular arrhythmias in infants and children
Am J Cardiol
(1994) - et al.
Atrial flutter in the young: a collaborative study of 380 cases
J Am Coll Cardiol
(1985) - et al.
Long-term follow-up of amiodarone therapy in the young: continued efficacy, unimpaired growth, moderate side effects
J Am Coll Cardiol
(1990) - et al.
Pharmacology, pharmacodynamics, and pharmacokinetics of sotalol
Am J Cardiol
(1990) Expanding clinical role of unique class III antiarrhythmic effects of sotalol
Am J Cardiol
(1990)
Cited by (59)
Adverse event rate during inpatient sotalol initiation for the management of supraventricular and ventricular tachycardia in the pediatric and young adult population
2020, Heart RhythmCitation Excerpt :Of the 5 patients with AEs on sotalol at 1-year follow-up, 2 were still on sotalol therapy, 1 was on flecainide therapy, 1 was on no antiarrhythmic therapy, and 1 underwent ablation 2 months after initial inpatient discharge (Table 5). This study supports the finding that sotalol is a safe and effective agent for the treatment of supraventricular and ventricular arrhythmias in the pediatric population.7,10,11 The major findings in this study included the following: first, the AE rate was 3%, including hemodynamically stable bradycardia and a statistically, but not clinically, significant change in QTc during sotalol initiation when corrected for QRS duration; second, none of the patients who had AEs required emergent intervention and none suffered from ventricular arrhythmias; third, all patients with AEs had congenital heart disease and were concomitantly on QT-prolonging agents; and finally, sotalol was acutely effective (defined as control of arrhythmia permitting discharge to outpatient follow-up) in 82% of patients, similar to that of previous studies in pediatric populations.10,12–14
Special Considerations for Ablation in Pediatric Patients
2019, Catheter Ablation of Cardiac ArrhythmiasEfficacy and adverse effects of sotalol in adults with congenital heart disease
2019, International Journal of Cardiology
- ☆
Supported by the Sean Roy Johnson Memorial Fund. Dr. Saul was supported by Clinical Investigator Award K08-HL02380-03 from the National Institutes of Health.